CSF2RB

Across TCGA pan-cancer cohorts, CSF2RB mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CSF2RB data layer compared with 27 for mass-spec protein and 12 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher CSF2RB mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CSF2RB expression acts as an unfavorable survival marker, although some lineages such as PDAC and COAD show a favorable association.

LUAD, PDAC, and COAD are the cancer types where CSF2RB mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	II,III,IV	0.670	0.973	.015	9	view →
PDAC	OS	Tertile	All	0.674	0.402	.023	9	view →
COAD	DFS	Median	IV	1.000	0.605	.043	6	view →
LSCC	DFS	Quartile	II,III,IV	0.229	0.888	.038	3	view →
GBM	OS	Median	All	0.902	0.735	.039	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CSF2RB–LUAD (DFS)

Open the LUAD breakdown →